Treatment-Resistant Bipolar Disorder: Reassessment and Care Options
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Treatment-resistant bipolar disorder refers to persistent symptoms or recurring mood episodes despite treatment that would ordinarily be expected to help. The meaning depends on the phase of bipolar illness: acute mania, bipolar depression, and long-term prevention require different interventions and different standards for judging response. A careful reassessment often matters as much as selecting another medication. CINP guidelines VA/DoD guideline
The clinical task is to establish what the patient is experiencing now, whether previous treatments were appropriate and adequately tried, what improved, what remained disabling, and which medical or practical barriers complicated care. This article examines accepted and proposed definitions, reassessment methods, treatment options, monitoring, safety, and the implications for recovery. Treatment choices require individualized psychiatric evaluation. NIMH overview
For additional clinical context, see Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care and Electroconvulsive Therapy for Bipolar Disorder: When It Is Considered.
What is treatment-resistant bipolar disorder?
The phrase describes an inadequate response to treatment in a person with bipolar disorder, but there is no single universally accepted definition that covers all mood phases and illness courses. A person whose manic episodes respond to lithium may still have recurrent bipolar depression. Another person may recover from acute episodes but relapse repeatedly during maintenance treatment. A third may have persistent mania despite multiple appropriate antimanic interventions. These problems should be described separately, because the evidence for managing them is different. Fountoulakis et al. CANMAT/ISBD
Treatment resistance is a clinical and research description rather than a separate DSM-5-TR or ICD-11 bipolar diagnosis. Bipolar I disorder, bipolar II disorder, cyclothymic disorder, and other bipolar presentations retain their diagnostic identities. The assessment should specify the current phase, severity, duration, functional impairment, prior treatments, and longitudinal course rather than use the term as a substitute for diagnostic formulation. NIMH VA/DoD
The 2025 ISBD definition of treatment-resistant bipolar depression
An International Society for Bipolar Disorders Task Force proposed in 2025 that treatment-resistant bipolar depression be defined in clinical-trial research by failure to achieve a clinically meaningful, sustained response following at least two consecutive approved acute-phase pharmacological treatments, each used at an adequate dose and duration with adherence. This is a phase-specific research consensus, not a universal clinical label for every form of hard-to-treat bipolar disorder. It is intended to make studies more comparable and assist the development of treatments. ISBD Task Force, 2025
A crucial nuance is that the Task Force listed different qualifying approved treatments for bipolar I and bipolar II depression. It included several antipsychotic-based options for bipolar I depression and a narrower approved list for bipolar II depression. The research definition did not treat every mood stabilizer or antidepressant trial as interchangeable with an approved acute bipolar depression trial. Excluding a drug from this particular operational definition does not mean that it has no clinical value. Vieta et al.
An earlier consensus proposed criteria for treatment-resistant and multi-therapy-resistant bipolar depression, considering treatment response, sustained remission, and different classes of intervention. Because definitions and endpoints differ, estimates of prevalence and treatment outcomes vary between studies. Clinically, partial response, failure of one adequate trial, ongoing residual symptoms, and failure of several well-documented trials convey different information. Hidalgo-Mazzei et al.
What about treatment-resistant mania?
Treatment-resistant mania is considered when clinically significant manic symptoms persist despite appropriate treatment. Severe mania can impair judgment, sleep, finances, relationships, and personal safety, with psychosis or hospitalization in some cases. A 2024 systematic review found that published definitions and evidence for treatment-resistant mania remain heterogeneous. These limitations reinforce the need to use established antimanic guidelines and individualized safety assessment rather than borrow criteria from treatment-resistant depression. Gonzalez-Torres et al. NICE
What about recurring episodes despite maintenance treatment?
Recurrence despite a preventive regimen raises questions about medication exposure, adherence, the polarity of new episodes, sleep and circadian disruption, substances, medical contributors, and whether the medication is effective for the relevant recurrence pattern. Treatment that stabilizes acute mania is not automatically sufficient for bipolar depression or long-term prevention. Maintenance outcomes require observation over time and should account for episode frequency, severity, functioning, and tolerability. CANMAT/ISBD NICE
What counts as an adequate treatment trial?
An adequate trial involves the right treatment for the right bipolar phase, a clinically appropriate dose or exposure, enough time to evaluate its likely benefit, and sufficiently consistent use. The duration required for antidepressant-phase therapies differs across approved drugs and cannot be replaced by a single universal cutoff. A course stopped after a few days because of adverse effects is important history, but it does not show that the same medicine was ineffective when adequately administered. ISBD Task Force
Clinicians should distinguish nonresponse, partial response, failure to attain remission, recurrence after an initial response, intolerance, contraindication, and inability to access treatment. These descriptions guide different decisions. Someone who improved markedly but experienced intolerable adverse effects presents a different clinical challenge from someone who took an adequately selected medication with no measurable improvement. An interrupted prescription may reveal access or adherence barriers rather than pharmacological resistance. Hidalgo-Mazzei et al. VA/DoD
Treatment response should be evaluated using the original target: acute depressive symptoms, manic symptoms, relapse prevention, or functional recovery. Structured symptom measures can support monitoring, but scales do not independently establish either bipolar diagnosis or treatment resistance. A useful response assessment also considers sleep, suicidal thinking, judgment, relationships, work, adverse effects, and the person's priorities. NIMH VA/DoD
First reassessment: check the diagnosis and the episode
A specialist evaluation reconstructs the longitudinal history of mania or hypomania, major depression, mixed symptoms, psychosis, hospitalizations, treatment-induced mood changes, substance use, family history, and functioning between episodes. With the patient's consent, observations from someone who knew the person during a possible manic or hypomanic period may help clarify the course. Bipolar I disorder requires a lifetime manic episode; bipolar II disorder involves hypomania and major depressive episodes without full mania. Bipolar II can still cause substantial disability. NIMH VA/DoD
A clinician must establish whether present symptoms represent depression, mania, hypomania, depression with mixed features, another psychiatric condition, or a medication or substance effect. Depressed mood with agitation, racing thoughts, rising energy, and reduced sleep may call for an assessment of mixed features or emerging mania. Psychotic symptoms require examination of their relationship to mood episodes. These distinctions affect the safety and likely effectiveness of treatments. CANMAT/ISBD NICE
Differential diagnosis and co-occurring conditions
Unipolar major depression, anxiety disorders, obsessive-compulsive disorder, ADHD, borderline personality disorder, and psychotic disorders can share some symptoms with bipolar illness or coexist with it. Clinical evaluation compares the onset, duration, triggers, and pattern of symptoms. Attention difficulties that remain persistent across years differ from attention changes that occur mainly during episodes. Emotional reactivity, impulsivity, and sleep changes likewise require context. A history of mood episodes remains central to establishing bipolar disorder. VA/DoD diagnostic guidance
Substance or medication exposure can contribute to apparent resistance. Alcohol, cannabis, stimulants, corticosteroids, some antidepressants, and withdrawal states may alter mood or sleep. Clinicians may also investigate thyroid disorders, neurologic disease, sleep disorders, and other physical conditions when the history suggests them. Low motivation, fatigue, cognitive slowing, tremor, and insomnia can reflect mood illness, adverse effects, or physical health problems. Assigning all symptoms to bipolar disorder can lead to unhelpful medication escalation. NICE VA/DoD
Where suicidal thoughts, severe agitation, psychosis, or impaired capacity to maintain safety are present, urgent risk assessment takes priority over routine diagnostic sequencing. The level of care may need to change immediately while diagnostic clarification continues. NICE urgent guidance
Second reassessment: reconstruct previous care
A useful medication history records what each drug was intended to treat; its start and stop dates; highest tolerated dose; relevant blood levels; concurrent treatments; clinical response; adverse effects; and the reason it was discontinued. It also records psychotherapy, ECT, medical illnesses, medication interactions, over-the-counter products, supplements, and substance exposure. A list of past drug names alone cannot demonstrate treatment resistance. VA/DoD ISBD
Adherence should be reviewed without blame. Sedation, weight changes, difficulty obtaining refills, complicated dosing schedules, cognitive symptoms, cost, stigma, and reproductive concerns can make a prescribed regimen difficult to sustain. A clinician can adjust the practical plan, treat adverse effects, coordinate pharmacy access, or consider an appropriate long-acting formulation when indicated. An intervention that cannot be taken consistently is unlikely to produce the results observed under controlled conditions. NICE VA/DoD
Laboratory tests can be informative, but only when interpreted correctly. Lithium concentrations require attention to timing, dose, kidney function, hydration, and interactions. For valproate, concentration testing may be appropriate when ineffectiveness, suspected nonadherence, or toxicity is a concern. Other medicines do not necessarily have a clinically validated concentration target. Laboratory data support the broader clinical picture; they are not a mechanical instruction to increase a dose. NICE medication monitoring
Third reassessment: identify the treatment phase
Acute mania, acute bipolar depression, and maintenance treatment have different evidence bases. In acute mania, controlling excessive energy, loss of sleep, psychosis, or unsafe behavior can be urgent. In acute bipolar depression, goals include relief of depressed mood, loss of pleasure, impaired functioning, and suicidal risk while protecting against destabilization. During maintenance, the primary target is prevention or reduction of future episodes and preservation of a sustainable long-term regimen. CANMAT/ISBD VA/DoD
Care options for persistent mania
Clinicians may optimize an appropriate antimanic drug, switch to an alternative evidence-supported agent, or combine an antipsychotic with lithium or valproate when indicated. Selection depends on prior response, current severity, psychosis, mixed features, age, medical conditions, reproductive risks, interactions, and adverse effects. Combinations sometimes improve outcomes but add burdens of monitoring and tolerability. Persistent severe mania warrants specialist management and may require inpatient care. NICE mania recommendations CANMAT/ISBD
Treatment-resistant mania studies are comparatively small and use varied criteria. Some specialist strategies involve complex off-label prescribing, but the existence of published case series does not establish a standard next treatment. A medication used in another psychiatric disorder cannot automatically be assumed effective for bipolar mania. Clinicians should explain the quality of evidence, anticipated monitoring, and what would count as success before pursuing such strategies. Gonzalez-Torres et al.
ECT may be considered for prolonged or severe mania after unsuccessful pharmacological treatment or when the condition is life-threatening. Decision-making includes medical assessment, anesthesia risks, memory-related adverse effects, and planning for maintenance therapy following improvement. NICE ECT recommendation VA/DoD
Care options for persistent bipolar depression
A treatment plan for bipolar depression begins by reviewing which therapies have evidence for that specific episode and subtype. Depending on regulatory jurisdiction and indication, relevant acute-phase options include quetiapine, lurasidone, cariprazine, lumateperone, and olanzapine combined with fluoxetine. Lithium and lamotrigine also have important clinical roles, including in preventive or combined strategies, but their evidence and licensed acute-phase indications differ from those of the approved agents included in the 2025 research definition. ISBD Task Force CANMAT/ISBD
Because bipolar I and bipolar II depression differ in available approved treatments, the adequacy of a prior trial should be evaluated against the correct diagnosis. The 2025 ISBD definition counts two approved qualifying pharmacological treatments given for sufficient duration with adherence, and it deliberately distinguishes its research standard from the broader clinical management of difficult-to-treat depression. A patient who tried two nonspecific antidepressants would not automatically meet the ISBD definition. Vieta et al.
Subsequent care may involve adjusting an insufficient but promising regimen, a planned switch, an evidence-supported combination, or a specialist evaluation for ECT. No single sequence is best for every person. History of manic switches, mixed features, psychosis, previous treatment benefit, metabolic health, physical illness, reproductive plans, and the patient's priorities all influence the choice. The clinical team should document the intended target and a review plan before making changes. CANMAT/ISBD CINP
Care options when relapses continue
The evaluation of recurring episodes asks what the existing maintenance regimen actually prevents. Lithium remains a major long-term treatment. Antipsychotics and other agents may be considered according to prior episode polarity, response, and adverse-effect profile. Frequent recurrences may reflect inadequate preventive coverage, inconsistent use, sleep disruption, or medical and substance-related factors. A medication that worked for one acute episode may have a different evidence profile during maintenance. NICE long-term recommendations CANMAT/ISBD
Relapse does not mean an existing treatment was completely ineffective: episodes may have become less frequent, less severe, or shorter. Remaining depression, sleep disruption, or functional impairment nevertheless deserves attention. Clinicians may retain a helpful preventive foundation while carefully addressing residual problems rather than automatically replacing every component of the regimen. NIMH NICE
Specialist interventions and their evidence
Electroconvulsive therapy for severe or resistant depression
ECT is performed under anesthesia with medical supervision. It can be considered for severe bipolar depression when multiple appropriate treatments have not helped or when there is an urgent need for improvement, including situations involving life-threatening deterioration. Memory disturbance, confusion, anesthesia-related risks, patient preferences, and the need for relapse-prevention care after ECT should be part of informed consent. VA/DoD NICE
A randomized trial in hospitalized patients with treatment-resistant bipolar depression found a higher clinical response rate with ECT than with algorithm-based medication treatment, although remission rates did not differ significantly between groups in that trial. The study supplies direct evidence for a specific resistant depressive population; its results should not be generalized to every bipolar phase or interpreted as a guarantee of lasting recovery. Follow-up treatment remains essential. Schoeyen et al.
Psychotherapy as an adjunct to medical care
Bipolar-focused psychotherapy can address sleep routines, stress, residual symptoms, interpersonal difficulties, relapse warning signs, treatment concerns, and family communication. Structured psychoeducation, family-focused therapy, cognitive behavioral therapy, and interpersonal and social rhythm therapy have evidence as adjunctive interventions. A systematic review and network meta-analysis found benefits for relapse-related outcomes in bipolar disorder, but those trials do not prove that psychotherapy alone reverses treatment-resistant acute mania or replaces indicated medication. Miklowitz et al.
Therapy goals should match the individual's difficulties. One person may need a plan for recognizing changes in sleep before mania; another may benefit from behavioral support during a prolonged depressive episode; another may need coordinated work with relatives following hospitalization. People should be able to discuss medication adverse effects and practical barriers as part of shared decision-making. NICE Miklowitz et al.
Ketamine, esketamine, TMS, and emerging approaches
Ketamine-based treatments, transcranial magnetic stimulation, and other interventions have been investigated for bipolar depression, including difficult-to-treat symptoms. The available studies differ in diagnostic populations, background medications, outcome duration, and evaluation of manic-switch risk. Short-term improvement in a small trial does not establish lasting recovery, and authorization for treatment-resistant major depressive disorder does not automatically establish approval for bipolar depression. These options require specialist evidence appraisal and careful monitoring. CINP ISBD
Before considering an emerging intervention, the team should clarify whether it is licensed for the patient's exact condition, whether adequately controlled bipolar studies support it, how dissociation, cardiovascular effects, sedation, cognitive effects, or mood elevation would be monitored, and what follow-up care is available. Commercial descriptions of a treatment as a cure or as universally effective are inconsistent with the current evidence. VA/DoD CANMAT/ISBD
Complex combinations and off-label care
When several documented phase-appropriate trials have failed, a mood-disorders specialist may evaluate combination treatments or carefully justified off-label strategies. More medications can increase metabolic, neurological, sedative, reproductive, and interaction risks. The benefit of an added medicine should be demonstrated against a prespecified clinical goal, with a plan for monitoring and removing unnecessary treatment burden where possible. CINP NICE
Essential medication safety checks
Lithium
Lithium is used in mania and maintenance and has evidence relevant to suicide-risk reduction in bipolar disorder. Monitoring involves serum lithium levels at appropriate intervals, kidney and thyroid function, calcium, electrolytes, hydration, and clinically important interactions. Vomiting, diarrhea, dehydration, fever, and certain drugs, including some anti-inflammatory medicines, can alter lithium exposure. New severe tremor, gait instability, confusion, or pronounced gastrointestinal symptoms warrant prompt medical evaluation. NICE lithium guidance NIMH medications
An apparently inadequate response does not automatically justify increasing lithium. Blood concentrations must be interpreted in context, including specimen timing, medical risk, symptoms, and tolerability. Abrupt discontinuation can increase relapse risk, so transitions should follow a supervised plan. NICE
Lamotrigine
Lamotrigine can be useful in certain bipolar depressive and maintenance strategies, particularly where depressive recurrence is prominent, but it is not a treatment for acute mania. It requires careful initiation and titration because of the risk of severe skin reactions, including Stevens-Johnson syndrome. Valproate can increase lamotrigine exposure. A new rash during dose escalation requires prompt clinical contact; rash with blistering, mucosal involvement, fever, or systemic illness requires urgent assessment. Restarting after an interruption may require a revised titration schedule. NICE lamotrigine guidance
Valproate
Valproate may be used in treatment of mania, but reproductive safety is central because prenatal exposure can cause birth defects and neurodevelopmental harm. Relevant regulations and restrictions must be checked in the treating jurisdiction, and risk-benefit decisions require specialist counseling. Monitoring also includes liver function, blood counts, weight or metabolic health, neurologic effects, and interactions. Pregnancy planning calls for timely coordinated specialist review rather than abrupt unsupervised discontinuation. NICE valproate guidance ACOG guideline
Antipsychotics
Antipsychotic medications have different evidence for acute mania, bipolar depression, and maintenance; they also differ in rates of sedation, weight gain, glucose and lipid changes, restlessness, movement disorders, prolactin-related effects, and cardiovascular risks. Monitoring typically covers weight, blood pressure, metabolic indicators, movement symptoms, and quality of life. An agent effective in one phase cannot automatically be assumed equally effective in another. CANMAT/ISBD NICE antipsychotic monitoring
Antidepressants
Selected people with bipolar depression may receive antidepressants as an adjunct to mood-stabilizing treatment, but antidepressant monotherapy is generally discouraged in bipolar I disorder. Risks include mood elevation, mixed symptoms, or destabilization, and treatment choices should reflect subtype, prior switches, and current symptoms. Two unsuccessful antidepressant trials do not automatically qualify as two approved bipolar-depression treatment failures under the ISBD 2025 research standard. NIMH ISBD
Medication decisions, including whether to stop or taper an ineffective prescription, should be made with the prescriber. Abrupt cessation may cause withdrawal symptoms or recurrence depending on the treatment. A change plan should explain the new therapeutic target, monitoring schedule, warning signs, and who to contact if symptoms worsen. NICE For details on treatment changes and relapse precautions, see Stopping Bipolar Medication: Withdrawal, Relapse, and Safer Planning.
Sleep, physical health, and functional recovery
Medical and behavioral contributors deserve attention because patients can remain impaired even after their most intense episode symptoms improve. Persistent insomnia, inconsistent sleep timing, metabolic illness, pain, substance use, and medication-related fatigue may interact with bipolar symptoms. A care plan may include regular sleep and wake times, suitable activity, treatment for co-occurring medical illness, and psychological strategies while maintaining the necessary psychiatric treatment. NICE Miklowitz et al.
Tracking sleep, increased energy, depressive symptoms, agitation, prescriptions, side effects, and significant events can help identify longitudinal patterns. A diary or app cannot diagnose bipolar disorder and should not treat ordinary mood fluctuations as episodes. Its value lies in supporting clinical discussions, individualized early-warning plans, and decisions about measurable change. Recovery also includes relationships, work or education, stable housing, and the ability to pursue personal goals. VA/DoD NIMH
Warning signs that require urgent help
Severe mania with escalating sleeplessness, dangerous behavior, agitation, psychosis, loss of judgment, or inability to meet basic needs needs urgent evaluation. Severe depression with suicidal intent, a plan to act, an inability to stay safe, or serious refusal of food and fluids also requires immediate clinical attention. Mixed depressive and manic symptoms may complicate assessment and increase the need for close monitoring. Emergency treatment can be appropriate before every aspect of the long-term diagnosis has been resolved. NICE VA/DoD
When there is immediate danger, call local emergency services or go to an emergency department. In the United States, people can call or text 988 for crisis support. A collaborative safety plan can identify personally relevant warning signs, trusted contacts, care-team numbers, emergency resources, and steps to reduce access to means of self-harm. Supporters can help the person connect with professional services and maintain immediate safety. NIMH
Special considerations across age and reproductive status
Bipolar I and bipolar II depression have different diagnostic histories and drug-approval evidence. Bipolar II is not a mild version of bipolar I; severe and recurrent depressive episodes can cause profound disability. The 2025 ISBD proposed trial definition explicitly recognizes subtype-specific approved treatment lists. Assessment and treatment should reflect the actual patient's course rather than apply a uniform resistance checklist. ISBD NIMH
Children and adolescents need developmentally informed specialist assessment because irritability, sleep changes, behavioral problems, and attention difficulties have many potential explanations. Evidence for resistant episodes in adults cannot simply be transferred to pediatric patients, and age-specific approvals and medication monitoring require review. NICE child and adolescent guidance
Older adults may have changes in kidney function, polypharmacy, neurological illness, cognitive difficulties, and greater susceptibility to falls, sedation, or drug interactions. These factors affect both symptom interpretation and safe medication selection. Monitoring plans should incorporate the person's physical-health profile and evolving treatment exposure. NICE monitoring
Pregnancy, postpartum, and reproductive planning call for coordinated obstetric and psychiatric evaluation. Some medicines, notably valproate, have major reproductive risks, while recurrence after stopping effective treatment may also carry serious consequences. The plan should consider prior episodes, the exact medication, available alternatives, fetal and maternal risks, lactation, and follow-up care. Pregnancy alone is not a reason to make an abrupt independent medication change. ACOG Clinical Practice Guideline No. 5
What a high-quality care plan should contain
A meaningful reassessment produces an agreed account of the current episode and prior treatment trials, a clear next therapeutic target, a rationale for changing or retaining medication, and an outcome-monitoring schedule. The team should explain likely benefits, important adverse effects, necessary laboratory testing, what counts as improvement, and when another review will occur. A collaborative plan also addresses access to medication, psychotherapy, sleep, physical health, and relapse or crisis response. VA/DoD NICE
Family members and partners can be helpful when the person agrees to their involvement. Their role may include observing personally relevant warning signs, supporting appointments, discussing agreed safety actions, and listening to concerns about side effects. Repeated unsuccessful trials can be demoralizing, so preserving patient choice and measuring functional improvements are central elements of care. Miklowitz et al.
Common misconceptions
Treatment resistance does not mean that improvement is permanently impossible. It describes an inadequate outcome under specified circumstances and often creates a reason for a fresh specialist review. It also does not prove that the original diagnosis was mistaken, although reassessment can reveal misclassification or previously overlooked co-occurring conditions. A failed or poorly tolerated course and an adequate nonresponsive course have different implications. ISBD VA/DoD
Another misconception is that more medication always means better care. Combinations can be appropriate, but they may increase interactions, sedation, metabolic changes, and monitoring burden. Likewise, a treatment effective for unipolar depression should not automatically be assumed suitable for bipolar depression, particularly where mania, hypomania, or mixed features matter. The right question is which intervention addresses the defined problem with the strongest available evidence and acceptable risks. CANMAT/ISBD
Frequently asked questions
How many medications must fail before bipolar disorder is treatment-resistant?
There is no universal number for all bipolar phases. The ISBD 2025 proposal for treatment-resistant bipolar depression calls for two approved, adequate acute-depression trials with adherence and a sustained failure of meaningful response. Resistant mania and repeated maintenance-phase relapses require other assessments. A list of two medicines by itself is not sufficient. ISBD Gonzalez-Torres et al.
Can depression be resistant while mania is controlled?
Yes. Acute depression and mania are different clinical phases, and medications have different effects across them. A preventive antimanic regimen may continue to provide benefit even when additional targeted treatment for depression is necessary. CANMAT/ISBD
Does resistance mean the diagnosis was wrong?
It calls for revisiting episode history, mixed features, other diagnoses, medical contributors, substances, and treatment exposure. Some people have accurately diagnosed bipolar illness with difficult-to-treat episodes, while others have co-occurring conditions that need their own treatment. Assessment requires a qualified clinician. VA/DoD
Is electroconvulsive therapy an option?
ECT is an evidence-supported option in selected severe bipolar depressive episodes, including some resistant cases, and may be considered in prolonged severe mania. A controlled trial in resistant bipolar depression showed a stronger response signal for ECT than for an algorithm-based medication comparison, but remission and long-term outcomes require separate consideration. Its risks and benefits should be discussed with an experienced treatment team. Schoeyen et al. NICE
Can psychotherapy help after medications have failed?
Psychotherapy can strengthen relapse prevention, symptom monitoring, daily routines, family communication, and coping, with randomized evidence supporting adjunctive treatments. It does not replace acute medical care for severe mania, psychosis, or other urgent situations. Miklowitz et al.
Is ketamine or TMS a proven cure?
No treatment should be described as a guaranteed cure for resistant bipolar depression. Evidence for emerging interventions varies in diagnostic population, treatment setting, duration, and safety monitoring. An indication for resistant major depressive disorder should not be transferred automatically to bipolar depression. CINP
Does treatment resistance require hospitalization?
The care setting depends on severity and safety. Some patients can receive specialist assessment and treatment in an outpatient program. Severe mania, psychosis, inability to maintain safety, or imminent suicide risk may require urgent hospital assessment. NICE
Should someone stop medication if it seems ineffective?
Prescription changes require collaboration with the treating clinician. Abrupt stopping may cause withdrawal problems or relapse, and some drugs require laboratory monitoring or carefully timed adjustments. A supervised plan identifies a target, an alternative approach, and warning signs. NICE
What is useful to bring to a specialist consultation?
A timeline of mood episodes, dates of hospitalization, a medication history with doses and reasons for stopping, laboratory results, sleep changes, medical illness, substance exposure, treatments already tried, and the person's goals can make reassessment more precise. With permission, a family member may contribute observations from earlier episodes. VA/DoD
Related Articles
References
American College of Obstetricians and Gynecologists. (2023). Treatment and management of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 5. Official guideline
Fountoulakis, K. N., Yatham, L. N., Grunze, H., et al. (2020). The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder. International Journal of Neuropsychopharmacology, 23(4), 230–256. DOI
Gonzalez-Torres, C., Mulsant, B. H., Husain, M. I., Alda, M., Young, R. C., & Ortiz, A. (2024). Challenges in defining treatment-resistant mania in adults: A systematic review. Bipolar Disorders, 26(1), 7–21. DOI
Hidalgo-Mazzei, D., Berk, M., Cipriani, A., et al. (2019). Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: Consensus definition. British Journal of Psychiatry, 214(1), 27–35. DOI
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI
Miklowitz, D. J., Efthimiou, O., Furukawa, T. A., et al. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry, 78(2), 141–150. DOI
National Institute for Health and Care Excellence. (2014, subsequently updated). Bipolar disorder: Assessment and management. CG185. Official guidance
National Institute of Mental Health. (n.d.). Bipolar disorder. Official resource
National Institute of Mental Health. (n.d.). Mental health medications. Official resource
Schoeyen, H. K., Kessler, U., Andreassen, O. A., et al. (2015). Treatment-resistant bipolar depression: A randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. American Journal of Psychiatry, 172(1), 41–51. DOI
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of bipolar disorder. Official guideline
Vieta, E., McIntyre, R. S., Suppes, T., et al. (2025). Defining treatment-resistant bipolar depression: Recommendations from the ISBD Task Force. Bipolar Disorders, 27(6), 411–423. DOI